Erudio Healtherudio.com
Drug
INCB161734 trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying INCB161734: DAWN-303. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 1 more trial with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| DAWN-303 NCT07522073 · Incyte Corporation | previously untreated KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma | Phase 3 | 58 | 15 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| INCB161734-101 NCT06179160 · Incyte Corporation FocusedView → | KRAS G12D-mutated advanced or metastatic solid tumors | Phase 1 | Focused | View | |||